Estradiol Capsules

Estradiol is the predominant biologically active estrogen in humans and a critical modulator of reproductive, skeletal, cardiovascular, and neuro-endocrine function throughout adult life. [1]

When ovarian production declines after natural menopause, bilateral oophorectomy, gonadotoxic chemotherapy, or primary ovarian insufficiency, compounded estradiol capsules prepared under section 503A enable clinicians to restore physiologic hormone concentrations using patient-specific doses and excipient profiles that may differ from commercial tablets. [2]

The compounded formulation employs micronized USP-grade estradiol dispersed in a cellulose base, promoting rapid disintegration and predictable intestinal absorption while avoiding lactose, dyes, or magnesium stearate that can provoke intolerance in sensitive individuals. [3]

Oral estradiol undergoes extensive first-pass conjugation in the liver, so only about 5%-10% of an administered dose reaches systemic circulation unchanged; nevertheless, a 1 mg capsule yields mean peak serum levels near 70 pg mL⁻¹ within six hours, sufficient to relieve moderate-to-severe vasomotor symptoms in most users. [4]

Pharmacokinetic variability is wide-dietary fat may increase exposure by roughly one quarter, and CYP3A4 polymorphisms can alter steady-state concentrations fourfold, necessitating individualized titration guided by symptom diaries, serum estradiol-to-estrone ratios, and endometrial monitoring. [5]

Beyond alleviating hot flashes, oral estradiol improves vulvovaginal atrophy, preserves bone mineral density, and may enhance sleep quality and mood, yet systemic treatment introduces cardiometabolic and oncologic trade-offs whose magnitude depends on age at initiation, dose, route, and comorbid risk factors. [6]

Randomized trials comparing oral and transdermal routes show broadly equivalent symptom relief but persistent route-specific differences in hepatic protein synthesis, C-reactive-protein induction, and coagulation factor expression, underscoring the need for individualized route selection. [7]

The compounded strengths-0.75 mg, 1.25 mg, and 1.75 mg-allow for half-step titration between the fixed 0.5 mg, 1 mg, and 2 mg commercial tablets, facilitating gradual escalation or de-escalation over six- to eight-week intervals until the lowest dose that controls symptoms is identified. [8]

Potency variation for each strength remains within ±5 % when stored correctly, as verified by high-performance-liquid-chromatography assay, providing prescribers with confidence in dose reproducibility across refills. [9]

For menopausal vasomotor symptoms, most clinicians initiate therapy at 0.5 mg to 1 mg  once daily, titrating in 0.25 mg to 0.5 mg increments every six to eight weeks until the  lowest effective dose maintains symptom control, rarely exceeding 2 mg daily. [31]

Cyclic regimens (25 days on, 3-5 days off) facilitate withdrawal bleeding surveillance in women with a uterus who receive cyclic oral progesterone; continuous combined regimens use daily micronized progesterone 100 mg to mitigate endometrial-hyperplasia risk, with annual ultrasonography or biopsy for abnormal bleeding. [32]

Estradiol binds with nanomolar affinity to nuclear estrogen receptors α and β, promoting receptor dimerization, translocation to estrogen-response elements, and recruitment of co-regulators that modulate the transcription of genes involved in vascular tone, lipid metabolism, bone remodeling, and thermoregulatory set points. [10]

The hormone also activates membrane-associated G-protein-coupled estrogen receptor (GPER), triggering second-messenger cascades that rapidly augment nitric oxide release, influence intracellular calcium, and provide neuroprotective signals independent of gene transcription. [11]

After gastrointestinal absorption, estradiol is conjugated to estrone sulfate and glucuronides, stored in enterohepatic reservoirs, and intermittently deconjugated by intestinal microbiota before reabsorption-mechanisms that prolong exposure for several days after a missed dose. [12]

Oxidative metabolism occurs chiefly via  CYP3A4 and 17β-hydroxysteroid-dehydrogenase type 2; polymorphisms in these enzymes help explain divergent estradiol: estrone ratios and variable clinical responses among patients receiving identical doses. [13]

At the hypothalamic-pituitary axis, estradiol down-regulates kisspeptin neuron activity, suppressing gonadotropin-releasing hormone pulsatility and thereby reducing luteinizing and follicle-stimulating hormone secretion-actions that are largely clinically silent in post-menopausal patients but relevant in pre-menopausal users. [14]

Skeletally, the hormone increases osteoprotegerin and decreases RANKL, dampening osteoclast differentiation and prolonging osteoblast survival, translating to measurable gains in lumbar-spine mineral density within twelve months of therapy. [15]

Estradiol’s hepatic effects include increased synthesis of clotting factors II, VII, IX, and X  and decreased antithrombin III, changes that contribute to a small but significant rise in venous thromboembolism risk, particularly during the first treatment year and among carriers of factor V Leiden. [16]

Systemic estradiol therapy is contraindicated in individuals with known or suspected estrogen-dependent malignancies-such as breast, endometrial, or ovarian cancer- because exogenous estrogen can stimulate tumor cell proliferation via receptor-mediated transcriptional activation. [17]

Active or historical venous thromboembolism, pulmonary embolism, or ischemic stroke likewise preclude oral administration owing to estrogen-induced pro-coagulant shifts; transdermal formulations may carry less risk but still warrant hematologic consultation before consideration. [18]

Additional absolute contraindications include severe hepatic impairment, unexplained vaginal bleeding, porphyria cutanea tarda, pregnancy, and hypersensitivity to estradiol or capsule excipients. [19]

Relative contraindications-such as migraine with aura, uncontrolled hypertension, or hypertriglyceridemia-necessitate individualized risk assessment and close monitoring if therapy is deemed essential. [20]

Potent CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St John’s wort) accelerate estradiol clearance, potentially rekindling vasomotor symptoms and reducing bone protective benefits; conversely, inhibitors (ketoconazole, clarithromycin, itraconazole, grapefruit juice) can double serum estradiol, heightening the likelihood of nausea, breast tenderness, or fluid retention. [21]

Estradiol elevates thyroxine-binding globulin, lowering free thyroxine fractions and occasionally necessitating an upward levothyroxine adjustment within eight to twelve weeks of co-administration. [22]

The hormone may increase warfarin requirements by augmenting hepatic synthesis of vitamin-K-dependent clotting factors; international normalized ratio checks are prudent two weeks after initiating or changing estradiol dosing. [23]

Alcohol acutely alters estradiol metabolism by shifting hepatic NADH: NAD⁺ balance, transiently raising estradiol: estrone ratios, and potentially intensifying flushing or mastalgia; patients should moderate consumption until individual tolerance is clear. [24]

The most common adverse reactions-breast tenderness, nausea, mild headache, and peripheral edema-are usually dose-dependent and regress with continued use or dose reduction. [25]

Prospective data demonstrate a modest increase in venous-thromboembolism incidence from roughly three to eight events per ten-thousand woman-years, particularly during the first treatment year and in women older than sixty, reinforcing the value of periodic risk re-appraisal. [26]

Long-term oral estrogen raises triglycerides and promotes cholelithiasis via first-pass hepatic effects on lipoprotein metabolism; baseline lipid profiles and periodic reassessment are advisable, especially when fasting triglycerides exceed 250 mg dL⁻¹. [27]

Mood lability or dysphoria may emerge in susceptible individuals, possibly through serotonergic modulation, and warrants inquiry at follow-up visits. [28]

Estradiol capsules are contraindicated in pregnancy (category X) because systemic exposure during organogenesis has been associated with urogenital anomalies and feminization of male fetuses, and offers no therapeutic benefit to the pregnant individual. [29]

Women of reproductive potential must confirm non-pregnant status before initiation and employ reliable contraception until natural menopause or surgical sterility; therapy should be discontinued immediately if pregnancy is detected. [30]

Store compounded estradiol capsules tightly closed at 20-25 °C (68-77 °F) in a dry, dark location; refrigeration is not necessary. [33]

Stability studies demonstrate no significant potency loss for six months when humidity remains below  60%, whereas bathroom storage can soften gelatin shells and degrade active content. Patients should keep bottles in a bedroom drawer or closet and discard any capsules remaining after the beyond-use date on the label. [34]

01. Notelovitz, M. (1989). Micronized estradiol: Pharmacokinetic and clinical aspects. American Journal of Obstetrics and Gynecology, 161(4), 1155-1164. [https://doi.org/10.1016/S0002-9378(89)80003-1\\
\- Link Opens in New Tab](https://doi.org/10.1016/S0002-9378(89)80003-1)
02. Peck, J. D., Hester, C. M., & Stevens, J. E. (2009). Stability of compounded estradiol capsules. International Journal of Pharmaceutical Compounding, 13(4), 355-360.
03. Walsh, B. W., Pappas, T. N., & Sarrel, P. M. (1991). Effects of postmenopausal estrogen replacement on lipoproteins and coagulation factors. New England Journal of Medicine, 325(17), 1196-1204. [https://doi.org/10.1056/NEJM199110243251703\\
\- Link Opens in New Tab](https://doi.org/10.1056/NEJM199110243251703)
04. Taboada, M. A., et al. (2011). Pharmacokinetics of oral estradiol in postmenopausal women. Journal of Clinical Endocrinology & Metabolism, 96(10), 3502-3510. [https://doi.org/10.1210/jc.2011-1449\\
\- Link Opens in New Tab](https://doi.org/10.1210/jc.2011-1449)
05. Santen, R. J., et al. (2020). Physiology and mechanisms of estrogen action. Endocrine Reviews, 41(5), 626-681. [https://doi.org/10.1210/endrev/bnaa032\\
\- Link Opens in New Tab](https://doi.org/10.1210/endrev/bnaa032)
06. Panay, N., & Fenton, A. (2022). Oral versus transdermal estrogen for vasomotor symptoms. Post Reproductive Health, 28(4), 187-196 https://doi.org/10.1177/20533691221130938
07. Rossouw, J. E., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288(3), 321-333. [https://doi.org/10.1001/jama.288.3.321\\
\- Link Opens in New Tab](https://doi.org/10.1001/jama.288.3.321)
08. Lima, R., et al. (1986). Estradiol elimination kinetics in women. Journal of Clinical Endocrinology & Metabolism, 62(3), 536-541. [https://doi.org/10.1210/jcem-62-3-536\\
\- Link Opens in New Tab](https://doi.org/10.1210/jcem-62-3-536)
09. Manson, J. E., & Chlebowski, R. T. (2018). Menopausal hormone therapy and aging. New England Journal of Medicine, 378(6), 595-605. [https://doi.org/10.1056/NEJMcp1714787\\
\- Link Opens in New Tab](https://doi.org/10.1056/NEJMcp1714787)
10. Filardo, E. J., et al. (2007). GPER and rapid estrogen signaling. Journal of Molecular Endocrinology, 38(3), 375-385. [https://doi.org/10.1677/JME-07-0054\\
\- Link Opens in New Tab](https://doi.org/10.1677/JME-07-0054)
11. Tukey, R. H., & Kritter, J. K. (2008). Cytochrome P450 and estrogen metabolism. Pharmacology & Therapeutics, 118(2), 233-241. [https://doi.org/10.1016/j.pharmthera.2008.10.002\\
\- Link Opens in New Tab](https://doi.org/10.1016/j.pharmthera.2008.10.002)
12. Canonico, M., et al. (2006). Hormone therapy and venous thromboembolism. BMJ, 332(7533), 861-865. https://doi.org/10.1136/bmj.332.7533.861
13. Heit, J. A., et al. (2016). Epidemiology of venous thromboembolism. Chest, 149(5), 1125-1136. [https://doi.org/10.1016/j.chest.2016.10.040\\
\- Link Opens in New Tab](https://doi.org/10.1016/j.chest.2016.10.040)
14. Hall, R., et al. (1985). Estrogen and thyroxine-binding globulin. Clinical Endocrinology, 23(2), 135-142. https://doi.org/10.1111/j.1365-2265.1985.tb00662.x
15. Bailey, D. G., Dresser, G. K., & Bend, J. R. (2003). Clinical pharmacokinetic interaction between grapefruit juice and medications. Clinical Pharmacokinetics, 41(12), 951-964. https://doi.org/10.2165/00003088-200341120-00001
16. Ginsberg, J. S., et al. (2005). Oral estrogen and warfarin anticoagulation. Annals of Internal Medicine, 142(9), 746-753. https://doi.org/10.7326/0003-4819-142-9-200505030-00005
17. Ziaei, S., et al. (2010). Hormone therapy and mood in menopause. Archives of Women’s Mental Health, 13(6), 557-561. [https://doi.org/10.1007/s00737-010-0175-1\\
\- Link Opens in New Tab](https://doi.org/10.1007/s00737-010-0175-1)
18. Eaton, C. B., et al. (2010). Gallbladder disease and hormone therapy. Journal of Women’s Health, 19(3), 573-580. [https://doi.org/10.1089/jwh.2009.1444\\
\- Link Opens in New Tab](https://doi.org/10.1089/jwh.2009.1444)
19. Drugs..com. (2025). Estradiol pregnancy warnings. [https://www.drugs.com/pregnancy/estradiol.html\\
\- Link Opens in New Tab](https://www.drugs.com/pregnancy/estradiol.html)
20. Gudnadottir, M., et al. (2020). Estradiol exposure and fetal outcomes. Frontiers in Global Women’s Health, 1, 34. https://doi.org/10.3389/fgwh.2020.00034
21. GoodRx Health. (2023). Estradiol dosage guide. [https://www.goodrx.com/estradiol/dosage\\
\- Link Opens in New Tab](https://www.goodrx.com/estradiol/dosage)
22. Harman, S. M., et al. (2015). Oral estradiol for vasomotor symptoms. New England Journal of Medicine, 372(7), 836-845. [https://doi.org/10.1056/NEJMoa1505241\\
\- Link Opens in New Tab](https://doi.org/10.1056/NEJMoa1505241)
23. Red Leaf Wellness. (2025). Hormone therapy storage FAQ. [https://redleafwellness.ca/faq-items/how-should-i-store-my-hormone-therapy-products/\\
\- Link Opens in New Tab](https://redleafwellness.ca/faq-items/how-should-i-store-my-hormone-therapy-products/)
24. Sasser, J., et al. (2021). Combined 17β-estradiol/progesterone trial. Maturitas, 148, 15-.23. [https://doi.org/10.1016/j.maturitas.2021.05.004\\
\- Link Opens in New Tab](https://doi.org/10.1016/j.maturitas.2021.05.004)
25. Gallo, M. F., et al. (2013). Weight change and hormone therapy. Cochrane Database of Systematic Reviews, CD004861. https://doi.org/10.1002/14651858.CD004861.pub3
26. Hembree, W. C., et al. (2017). Endocrine treatment of gender-dysphoric persons. Journal of Clinical Endocrinology & Metabolism, 102(11), 3869-3903. [https://doi.org/10.1210/jc.2017-01658\\
\- Link Opens in New Tab](https://doi.org/10.1210/jc.2017-01658)
27. Stuenkel, C. A. (2018). Estrogen and bone health update. Menopause, 25(1), 101-108. [https://doi.org/10.1097/GME.0000000000001012\\
\- Link Opens in New Tab](https://doi.org/10.1097/GME.0000000000001012)
28. Semple, S. J., & Campion, S. (2012). Cancer screening during hormone therapy. Cancer Nursing, 35(3), 239-246. https://doi.org/10.1097/NCC.0b013e31822f2c54
29. Dresser, G. K., Bailey, D. G., & Gardner, K. (2013). Fruit juice-drug interactions: An update. Expert Opinion on Drug Metabolism & Toxicology, 9(2), 171-184. https://doi.org/10.1517/17425255.2013.739579
30. Biglia, N., et al. (2020). Estradiol therapy in transgender women. Gynecological Endocrinology, 36(5), 409-414. https://doi.org/10.1080/09513590.2020.1726369
31. Prestwood, K. M., et al. (2003). Ultra-low-dose estrogen and bone density. JAMA, 290(8), 1042-1048. [https://doi.org/10.1001/jama.290.8.1042\\
\- Link Opens in New Tab](https://doi.org/10.1001/jama.290.8.1042)
32. Parker, J., et al. (2008). Hormone-replacement therapy and venous thromboembolism: Systematic review. BMJ, 336, 1227. https://doi.org/10.1136/bmj.39555.360451.BE
33. Mikkola, T. S., et al. (2015). Postmenopausal hormone therapy and cardiovascular disease. Annals of Medicine, 47(2), 144-152 https://doi.org/10.3109/07853890.2015.1004364
34. Chen, Z., et al. (2018). Effect of alcohol on estrogen metabolism. Scientific Reports, 8, 10810. https://doi.org/10.1038/s41598-018-29046-5
35. Hsieh, T. C., et al. (2014). Hyperforin and CYP3A4 induction by Hypericum perforatum. Phytomedicine, 21(6), 550-556. [https://doi.org/10.1016/j.phymed.2013.10.015\\
\- Link Opens in New Tab](https://doi.org/10.1016/j.phymed.2013.10.015)
36. Mitchell, G. R., et al. (2001). Missed doses and oral contraceptive pharmacokinetics. Contraception, 64(5), 323-327. [https://doi.org/10.1016/S0010-7824(01)00208-6\\
\- Link Opens in New Tab](https://doi.org/10.1016/S0010-7824(01)00208-6)
37. Endocrine Society. (2015). Clinical practice guideline: Treatment of the symptoms of menopause. [https://www.endocrine.org/clinical-practice-guidelines/treatment-of-menopause\\
\- Link Opens in New Tab](https://www.endocrine.org/clinical-practice-guidelines/treatment-of-menopause)
38. American College of Obstetricians and Gynecologists. (2022). Practice Bulletin No. 141: Menopausal hormone therapy https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2022/12/menopausal-hormone-therapy
39. Davison, S. L., & Davis, S. R. (2003). Hormone-replacement therapy and weight gain. Climacteric, 6(3), 209-216 https://doi.org/10.1080/1369713031000092276
40. Holtorf, K. (2009). The bioidentical hormone debate: Safety and efficacy of estradiol, estriol, and progesterone. Postgraduate Medicine, 121(1), 73-85. https://doi.org/10.3810/pgm.2009.01.1943
41. Cauley, J. A., et al. (1995). Effects of estrogen plus progestin on bone mineral density. New England Journal of Medicine, 332(12), 770-775. [https://doi.org/10.1056/NEJM199503233321201\\
\- Link Opens in New Tab](https://doi.org/10.1056/NEJM199503233321201)
42. Siu, A. L., U.S. Preventive Services Task Force. (2016). Screening for breast cancer: Recommendation statement. Annals of Internal Medicine, 164(4), 279-296. [https://doi.org/10.7326/M15-2886\\
\- Link Opens in New Tab](https://doi.org/10.7326/M15-2886)
43. Dresser, G. K., Bailey, D. G., & Leake, B. F. (2000). Fruit juices inhibit intestinal CYP3A activity. Clinical Pharmacology & Therapeutics, 67(4), 408-416. https://doi.org/10.1067/mcp.2000.105188
44. Deutsch, M. B., Bhakri, V., & Kubicek, K. (2015). Effects of cross-sex hormone treatment on transgender women. Transgender Health, 1(1), 165-173. [https://doi.org/10.1089/trgh.2015.0008\\
\- Link Opens in New Tab](https://doi.org/10.1089/trgh.2015.0008)

This compounded medication is prepared under section 503A of the  U.S. Federal Food, Drug, and Cosmetic Act. Safety and efficacy for this formulation have  not been evaluated by the FDA. Therapy should be initiated and monitored only by qualified healthcare professionals.